3 Undervalued Healthcare Stocks Invstors Can Buy Right Now
Summary
Parkev states that the United States healthcare sector is experiencing a significant transformation, driven by current government policies aimed at shifting cost burdens to consumers and pressuring healthcare and pharmaceutical companies to lower prices. These changes introduce both opportunities and risks for investors. Parkev identifies three undervalued companies in this sector that he recommends buying.
Parkev emphasizes that these healthcare companies offer investors diversification from macroeconomic trends, as healthcare spending is less correlated with economic conditions. He also mentions his recently published book detailing his six-step investment framework for evaluating stocks.
Mentioned Stocks
Reasoning: Parkev rates Oscar Health highly for its effective integration of artificial intelligence to enhance operational efficiency and performance. He notes it as one of the fastest-growing healthcare companies since 2024, achieving an average annual revenue growth rate exceeding 40%. Management forecasts continued strong growth, projecting over 20% average annual revenue growth until 2030, supported by improved profitability through cost control. Parkev calculates a fair value of over $41 per share, suggesting an upside of more than 34% from its current market price, which is slightly above $30, within the next 12 to 18 months.
Reasoning: Parkev identifies Eli Lilly as a strong investment, primarily driven by the massive demand for weight-loss medications, which has significantly boosted its revenue and free cash flow. He projects the company's free cash flow to surge from $12 billion in 2025 to over $77 billion by 2032. Beyond this immediate growth driver, Parkev notes Eli Lilly's efforts to expand market availability and its extensive experience in research and development, suggesting a robust pipeline for future treatments that could replace existing ones as the market matures. He estimates a fair value of $1,494 per share, implying about a 30% upside from its current market price of $1,153 within the next 12 to 18 months. Parkev personally owns shares of Eli Lilly and is interested in adding more to his portfolio.
Reasoning: Parkev classifies Teladoc Health as a buy opportunity, noting its pandemic-era boom in revenue (over fivefold increase) due to telemedicine demand. Post-reopening, the business stagnated, with revenue peaking and even declining in one segment. The company is adapting by reducing advertising, improving efficiency, and increasing provider availability. Parkev maintains a positive long-term outlook, believing Teladoc will benefit from the increasing shift towards virtual healthcare visits. He calculates a fair value of $7.86 per share, indicating an approximate 30% upside from its current market price of $6.13 over the next 12 to 18 months.